New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
07:05 EDTOSIROsiris Therapeutics designated as Orphan Drug title holder by EMA
Osiris Therapeutics announced that the European Medicines Agency, or EMA, has designated Osiris as the Orphan Drug title holder for Prochymal. The EU Commission adopted the decision to transfer the designation of Prochymal as an orphan medicinal product under Regulation, or EC, No 141/2000 of the European Parliament and of the Council. The Decision will appear in the EU Community Register of Orphan Medicinal Products.
News For OSIR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 4, 2016
07:25 EDTOSIROsiris price target lowered to $4 from $8 at Brean Capital
Subscribe for More Information
February 3, 2016
16:34 EDTOSIROsiris appoints Chief Business OfficerDwayne Montgomery as Interim CEO
Subscribe for More Information
February 2, 2016
11:03 EDTOSIROsiris price target lowered to $18.50 from $28 at Piper Jaffray
Subscribe for More Information
08:01 EDTOSIROsiris announces 100% Medicare coverage for Grafix
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use